The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein] Doxazosin results in increased activity of ADRA2A protein Doxazosin results in decreased expression of ADRA2A protein
Doxazosin results in increased expression of BAX protein SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]
[Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein; Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein; Lithocholic Acid inhibits the reaction [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein]
Doxazosin results in increased expression of NPPB protein [Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA
[Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein
SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein] SERPINB5 protein results in increased susceptibility to Doxazosin
Doxazosin results in increased expression of SMAD4 mRNA; Doxazosin results in increased expression of SMAD4 protein SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]
BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein] Doxazosin results in decreased expression of VEGFA mRNA; Doxazosin results in decreased expression of VEGFA mRNA alternative form; Doxazosin results in decreased expression of VEGFA protein